Phase 1 Study Begins to Evaluate AGMB-447 for IPF

 

Right now, there are minimal therapeutic interventions for people living with idiopathic pulmonary fibrosis (IPF). Because of this, IPF comes with a life expectancy of 3-5 years past diagnosis. While people with IPF can undergo a lung transplant, better treatment options are urgently needed. It is crucial to advance research around IPF to identify potential treatments that could improve the lives of those affected.  This is what Agomab Therapeutics NV (“Agomab”) is working to do by developing AGMB-447.

Agomab describes AGMB-447 as:

an inhaled small molecule lung-restricted inhibitor of ALK5 (of TGFβR1). AGMB-447 is specifically designed to inhibit ALK5 in the respiratory tract while avoiding clinically relevant systemic exposure through rapid hydrolyzation in the bloodstream [and] aims to reverse fibrosis in these patients.

Recently, Agomab launched a Phase 1 clinical study to evaluate AGMB-447 for idiopathic pulmonary fibrosis. Both healthy individuals and people living with IPF are included in this study; altogether, 76 individuals have enrolled. During the course of the trial, researchers will evaluate both a single and multiple ascending dose of AGMB-447. The researchers hope to identify how safe and well-tolerated the treatment is, as well as its pharmacokinetic profile.

Learn About Idiopathic Pulmonary Fibrosis (IPF)

  • Idiopathic: of an unknown cause
  • Pulmonary: relating to the lungs
  • Fibrosis: tissue thickening/scarring

Idiopathic pulmonary fibrosis is a rare condition in which the lungs stiffen and scar from an unknown cause. As the lungs become increasingly scarred, oxygen is unable to enter the bloodstream. People with IPF often find it difficult to breathe. Idiopathic pulmonary fibrosis exists under the greater umbrella of interstitial lung disease. Although IPF is idiopathic, as the name states, some doctors hypothesize that people with IPF are genetically predisposed to this condition; this is then triggered by environmental factors such as viral infections, cigarette smoke, or metal/wood dust.

IPF most often occurs in people between ages 50 and 70. An estimated 100,000 people in the United States are living with IPF. This condition can be difficult to diagnose, especially in early stages, because symptoms often develop slowly over time. Potential symptoms related to IPF may include:

  • Shortness of breath and/or difficulty breathing
  • Blood clots in the lungs
  • Gastroesophageal reflux
  • A dry, hacking cough
  • Appetite loss
  • Losing weight without trying
  • Increased risk of lung cancer and pneumonia
  • Clubbed fingernails and toenails
Jessica Lynn

Jessica Lynn

Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.

Follow us